📊 LGNZZ Key Takeaways
Is Ligand Pharmaceuticals Inc. (LGNZZ) a Good Investment?
Ligand demonstrates strong fundamental health with 60.4% revenue growth, fortress-like balance sheet (0.03x D/E ratio), and positive free cash flow generation. However, net income growth appears driven by non-operating items rather than core business expansion, creating sustainability concerns around reported profitability.
Ligand shows strong fundamentals with 60%+ revenue growth, solid operating profitability, and robust free cash flow from an asset-light model. A fortress balance sheet with minimal debt and exceptional liquidity reduces financial risk. While the net income spike appears boosted by non-operating items, underlying cash generation supports a positive outlook.
Why Buy Ligand Pharmaceuticals Inc. Stock? LGNZZ Key Strengths
- Strong revenue growth of 60.4% YoY demonstrates market demand and business expansion
- Fortress balance sheet with minimal debt (27.5M), exceptional liquidity (22.23x current ratio), and 174.9M in cash
- Positive operating cash flow (49.4M) and free cash flow (48.9M) indicate underlying business generates real cash
- Very low leverage (0.03x D/E) provides financial flexibility for growth investments or shareholder returns
- Exceptionally strong liquidity and low leverage
- Robust YoY revenue growth with positive operating margin
- Consistent free cash flow with minimal capex needs
LGNZZ Stock Risks: Ligand Pharmaceuticals Inc. Investment Risks
- Net income growth of 3186.6% appears inflated by non-operating items; operating income only 33% of net income signals one-time gains or unusual items unlikely to repeat
- Disconnect between operating margin (15.3%) and net margin (46.4%) indicates sustainability risk in reported profitability
- Pharmaceutical sector subject to regulatory, clinical trial, and intellectual property risks; high insider activity (16 Form 4s in 90 days) may indicate profit-taking
- Sustainability of 60.4% revenue growth uncertain; high current ratio (22.23x) suggests potential capital inefficiency or defensive cash positioning
- Revenue volatility from milestone/royalty timing and partner dependence
- Concentration and patent/regulatory exposure typical of pharma royalties
- Earnings quality concerns from non-operating gains inflating net margin
Key Metrics to Watch
- Organic revenue growth trends and mix of licensing/non-operating income vs core product revenue
- Operating income and operating margin sustainability to validate net income quality
- Operating cash flow consistency and FCF conversion rate to confirm cash generation capability
- Royalty revenue % of total
- Operating cash flow / Operating income (cash conversion)
Ligand Pharmaceuticals Inc. (LGNZZ) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 22.23x current ratio provides a solid financial cushion.
LGNZZ Profit Margin, ROE & Profitability Analysis
LGNZZ vs Healthcare Sector: How Ligand Pharmaceuticals Inc. Compares
How Ligand Pharmaceuticals Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Ligand Pharmaceuticals Inc. Stock Overvalued? LGNZZ Valuation Analysis 2026
Based on fundamental analysis, Ligand Pharmaceuticals Inc. appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Ligand Pharmaceuticals Inc. Balance Sheet: LGNZZ Debt, Cash & Liquidity
LGNZZ Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Ligand Pharmaceuticals Inc.'s revenue has remained relatively flat over the 5-year period, with a 3% decline. The most recent EPS of $2.94 reflects profitable operations.
LGNZZ Revenue Growth, EPS Growth & YoY Performance
LGNZZ Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $51.8M | -$7.2M | $-0.39 |
| Q2 2025 | $41.5M | $4.8M | $0.24 |
| Q1 2025 | $31.0M | -$42.5M | $-2.21 |
| Q3 2024 | $32.9M | $2.3M | $-0.39 |
| Q2 2024 | $26.4M | $2.3M | $0.13 |
| Q1 2024 | $31.0M | $41.9M | $2.33 |
| Q3 2023 | $32.9M | $404.0K | $0.02 |
| Q2 2023 | $26.4M | -$895.0K | $-0.05 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Ligand Pharmaceuticals Inc. Dividends, Buybacks & Capital Allocation
LGNZZ SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Ligand Pharmaceuticals Inc. (CIK: 0000886163)
📋 Recent SEC Filings
❓ Frequently Asked Questions about LGNZZ
What is the AI rating for LGNZZ?
Ligand Pharmaceuticals Inc. (LGNZZ) has a Combined AI Rating of BUY from Claude (BUY) and ChatGPT (BUY) with 74% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are LGNZZ's key strengths?
Claude: Strong revenue growth of 60.4% YoY demonstrates market demand and business expansion. Fortress balance sheet with minimal debt (27.5M), exceptional liquidity (22.23x current ratio), and 174.9M in cash. ChatGPT: Exceptionally strong liquidity and low leverage. Robust YoY revenue growth with positive operating margin.
What are the risks of investing in LGNZZ?
Claude: Net income growth of 3186.6% appears inflated by non-operating items; operating income only 33% of net income signals one-time gains or unusual items unlikely to repeat. Disconnect between operating margin (15.3%) and net margin (46.4%) indicates sustainability risk in reported profitability. ChatGPT: Revenue volatility from milestone/royalty timing and partner dependence. Concentration and patent/regulatory exposure typical of pharma royalties.
What is LGNZZ's revenue and growth?
Ligand Pharmaceuticals Inc. reported revenue of $268.1M.
Does LGNZZ pay dividends?
Ligand Pharmaceuticals Inc. does not currently pay dividends.
Where can I find LGNZZ SEC filings?
Official SEC filings for Ligand Pharmaceuticals Inc. (CIK: 0000886163) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LGNZZ's EPS?
Ligand Pharmaceuticals Inc. has a diluted EPS of $6.13.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is LGNZZ a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Ligand Pharmaceuticals Inc. has a BUY rating with 74% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is LGNZZ stock overvalued or undervalued?
Valuation metrics for LGNZZ: ROE of 12.2% (sector avg: 15%), net margin of 46.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy LGNZZ stock in 2026?
Our dual AI analysis gives Ligand Pharmaceuticals Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is LGNZZ's free cash flow?
Ligand Pharmaceuticals Inc.'s operating cash flow is $49.4M, with capital expenditures of $452.0K. FCF margin is 18.2%.
How does LGNZZ compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 46.4% (avg: 12%), ROE 12.2% (avg: 15%), current ratio 22.23 (avg: 2).